Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gram-negative bacterial outer membrane lipids, primarily lipopolysaccharide (LPS), are essential structural components that constitute the outer leaflet of the bacterial outer membrane. LPS is a complex glycolipid consisting of three distinct regions: the hydrophobic Lipid A, which anchors the molecule in the membrane; a core oligosaccharide; and the O-antigen polysaccharide chain (1). These lipids function as a critical permeability barrier, protecting the cell from environmental stressors, host immune factors, and various classes of antibiotics (2). In clinical settings, LPS is recognized as a potent endotoxin; its release during bacterial lysis triggers an intense inflammatory response via the TLR4 signaling pathway, which can progress to life-threatening sepsis and septic shock (3). Therapeutic strategies targeting these lipids include the use of polymyxins, which bind to Lipid A to disrupt membrane stability, and the development of novel small molecules that inhibit the transport of LPS to the cell surface (4). Given the rise of multidrug-resistant Gram-negative pathogens, these lipids represent a vital target for both direct antimicrobial action and the neutralization of systemic toxicity (5). Citations: (1) Raetz, C. R., & Whitfield, C. (2002). Lipopolysaccharide endotoxins. Annual Review of Biochemistry. (2) Nikaido, H. (2003). Molecular Basis of Bacterial Outer Membrane Permeability Revisited. Microbiology and Molecular Biology Reviews. (3) Steimle, A., et al. (2016). Structure and function of Lipid A. International Journal of Medical Microbiology. (4) Sperandeo, P., et al. (2019). The Lipopolysaccharide Transport Pathway of Gram-Negative Bacteria. Chemical Reviews. (5) Poirel, L., et al. (2017). Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms. Clinical Microbiology Reviews.
Drugs like polymyxins act by binding to the Lipid A component of lipopolysaccharides through electrostatic interactions, displacing stabilizing divalent cations (Ca2+ and Mg2+). This leads to the disruption of the outer membrane, increased permeability, and eventual cell death. Other therapeutic approaches involve inhibiting the transport of these lipids to the outer membrane (e.g., LptD inhibitors) or neutralizing the lipid's endotoxic activity by blocking its interaction with host immune receptors like TLR4.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial outer membrane lipids (LPS).